# An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

> **NCT02763761** · PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Renal Cell Carcinoma
- Melanoma
- Lung Cancer

## Interventions

- **DRUG:** Infliximab + Prednisone
- **DRUG:** Methylprednisolone + Prednisone

## Key facts

- **NCT ID:** NCT02763761
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08-16
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Insufficient enrollment
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02763761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02763761, "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02763761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*